Abstract
BackgroundThe minimal anticipated biological effect level (MABEL) approach is recommended for the selection of safe clinical starting dose for T-cell engagers (TCE). The approach allows to estimate the minimal recommended...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
